Prothionamide

DRUG2 trials

Sponsors

IUATLD, Inc, Beijing Chest Hospital

Conditions

MDR-TBPulmonary TuberculosisRifampicin-resistant Tuberculosis

Phase 3

The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

CompletedNCT02409290

IUATLD, IncMDR-TB

Start: 2016-03-31End: 2023-05-02Updated: 2023-09-28

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Active, not recruitingNCT06081361

Beijing Chest HospitalPulmonary Tuberculosis, Rifampicin-resistant Tuberculosis

Start: 2023-12-22End: 2026-12-31Target: 186Updated: 2025-04-01

Related Papers

T-wave morphology abnormalities in the STREAM stage 1 trial

Expert Opinion on Drug Safety2024-03-10

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.

2021-09-2522 citations

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

New England Journal of Medicine2019-03-13387 citations

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial

Trials2019-01-1629 citations